The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model.
Saved in:
| Title: | The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model. |
|---|---|
| Authors: | Gupta VG; Department of Obstetrics and Gynecology, Washington University School of Medicine, 660 S. Euclid Avenue, Mailstop 8064-37-1005, Saint Louis, MO, 63110, USA. ggupta@wustl.edu., Roby KF; Department of Cell Biology and Physiology, The University of Kansas Medical Center, Kansas City, KS, USA., Pathak HB; Department of Pathology, The University of Kansas Medical Center, Kansas City, KS, USA., Godwin AK; Department of Pathology, The University of Kansas Medical Center, Kansas City, KS, USA., Gunewardena S; Department of Cell Biology and Physiology, The University of Kansas Medical Center, Kansas City, KS, USA., Khabele D; Department of Obstetrics and Gynecology, Washington University School of Medicine, 660 S. Euclid Avenue, Mailstop 8064-37-1005, Saint Louis, MO, 63110, USA. khabeled@wustl.edu. |
| Source: | BMC cancer [BMC Cancer] 2025 Feb 11; Vol. 25 (1), pp. 233. Date of Electronic Publication: 2025 Feb 11. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
